Related Experiment Videos
[Hypoplastic leukemia successfully treated with low-dose aclarubicin: a case report]
E Toyota1, T Ohtsuki, N Kamiyama
1Department of Medicine, Kawasaki Medical School.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|September 1, 1991
Summary
Low-dose aclarubicin (LDACR) therapy effectively induced differentiation in a patient with hypoplastic acute myelogenous leukemia. This treatment led to the disappearance of myeloblasts and achieved complete remission, demonstrating its therapeutic potential.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Differentiation induction therapy is a key treatment for myelodysplastic syndromes and atypical leukemias.
- Low-dose aclarubicin (LDACR) is recognized for its role in differentiation induction therapy.
Observation:
- A 36-year-old female presented with hypoplastic acute myelogenous leukemia, characterized by pancytopenia and 35.4% myeloblasts in bone marrow.
- Symptoms included general fatigue upon admission.
Findings:
- The patient received 10 days of daily intravenous LDACR (20 mg).
- Post-treatment, peripheral blood myeloblasts disappeared, and pancytopenia resolved.
- Bone marrow examination showed increased nucleated cell counts, indicating complete remission.
Implications:
- LDACR therapy shows promise as an effective chemotherapy option for hypoplastic acute myelogenous leukemia.
- This case highlights the successful application of LDACR in achieving complete remission in a challenging leukemia subtype.
- Further investigation into LDACR's efficacy in similar cases is warranted.